M. Kizaki et al., A novel retinoic acid-resistant acute promyelocytic leukemia model in vitro and in vivo (review), INT J MOL M, 4(4), 1999, pp. 359-364
Differentiation-inducing therapy by all-trans retinoic acid (RA) is now a s
tandard therapy in patients with acute promyelocytic leukemia (APL). Nearly
all patients achieve complete remission by the treatment of all-trans RA,
however, clinical remissions are usually of brief duration, and these patie
nts often develop RA-resistant disease. The mechanisms of RA-resistance in
APL cells are poorly understood and most clinical approaches have not been
successful in overcoming RA-resistance. We have recently established a nove
l APL cell line (UF-1) with RA-resistant features. In addition, we have est
ablished human GM-CSF-producing transgenic (hGMTg) SCID mice system. UF-1 c
ells were inoculated either intraperitoneally or subcutaneously into hCMTg
SCID mice and made the first RA-resistant murine APL model. These RA-resist
ant APL model systems in vitro, and in vivo may be useful for investigating
the molecular studies on the block of leukemic cell differentiation and as
means to investigate the mechanisms of RA-resistance. Moreover, this murin
e model system will be important for developing novel therapeutic strategie
s in RA-resistant APL.